Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitura HealthASX:VIT +4.17% Equity-to-Asset is 0.60 as of Dec. 2025, which is 3% below its 10-year median of 0.62. The stock has 8 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Vitura Health ranks worse than 50.74% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vitura Health's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$46.1 Mil. Vitura Health's Total Assets for the quarter that ended in Dec. 2025 was A$76.9 Mil.
Therefore, Vitura Health's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.60.
The historical rank and industry rank for Vitura Health's Equity-to-Asset or its related term are showing as below:
ASX:VIT'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.54 Med: 0.62 Max: 0.88
Current: 0.6
During the past 7 years, the highest Equity to Asset Ratio of Vitura Health was 0.88. The lowest was 0.54. And the median was 0.62.
ASX:VIT's Equity-to-Asset is ranked worse than 50.74% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs ASX:VIT: 0.60
Vitura Health (ASX:VIT) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Vitura Health Equity-to-Asset Related Terms
Vitura Health Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Vitura Health's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Vitura Health's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Vitura Health's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitura Health (ASX:VIT) has a Equity-to-Asset of 0.60 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vitura Health and its competitors. This is near median its historical median of 0.62. Over the past decade, Vitura Health's Equity-to-Asset has ranged from 0.54 to 0.88. According to the industry distribution chart, Vitura Health ranks #511 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 50.7%.
Is Vitura Health's Equity-to-Asset too high?
Vitura Health's current Equity-to-Asset of 0.60 is near median its 10-year median of 0.62. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 0.88. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Vitura Health's value of 0.60 is 1.6% below this industry median. Based on the distribution chart, Vitura Health ranks #511 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Vitura Health's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #511 out of 1007 companies for Equity-to-Asset. This places Vitura Health in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Vitura Health's value of 0.60 is 1.6% below this benchmark. Historically, Vitura Health's own Equity-to-Asset has ranged from 0.54 to 0.88 over the past decade. While the company's 10-year median is 0.62 vs. the industry median of 0.61, Vitura Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitura Health's current Equity-to-Asset of 0.60 is 1.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vitura Health and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current Equity-to-Asset is 0.60, which is near median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.09, compared to a current price of A$0.03 — trading 72.2% below its estimated fair value. The current Equity-to-Asset is 0.60, which is near median its 10-year median of 0.62 and 1.6% below the Drug Manufacturers industry median of 0.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current Equity-to-Asset is 0.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 
